As mega-cap tech stocks' dominance wanes, Zacks Investment Research identifies five non-technology stocks poised for growth in 2026: MasTec (AI infrastructure), Caterpillar (construction/mining), Walmart (retail/e-commerce), Eli Lilly (pharmaceuticals/weight loss drugs), and Howmet Aerospace (aerospace/defense). All five are trading at 5-year highs with expected double-digit earnings growth, though valuations are elevated with forward P/E ratios ranging from 30 to 56.

Nvidia experienced profit-taking after earnings despite beating expectations, but analyst maintains $300 price target by end of 2026 and $500 by decade's end. Data center stocks also beat guidance with rising backlogs. Market volatility was driven by Blue Owl's private credit redemption freeze, impacting financial stocks. Despite recent volatility, strong economic growth and accommodative Fed policy are expected to support stock market momentum.

PatentVest released an analysis of 1,200+ patent documents across 50 oral small-molecule GLP-1 programs, revealing dramatic disparities in patent defensibility among competitors. With injectable GLP-1s reaching only 5% of eligible patients and clinical efficacy converging around 12-16% weight loss, long-term market dominance will depend on patent portfolio strength rather than clinical performance alone. Major patent cliffs for semaglutide (2031) and tirzepatide (2036) will determine which assets become franchises versus facing generic competition.

Hims & Hers Health stock has declined 70% over the past year due to slowing GLP-1 drug sales after FDA ended shortage declarations and competitors cut prices. Q4 2025 earnings beat on profit but missed on sales, with quarterly growth halving to 28% from full-year 59%. However, management emphasizes that the majority of revenue comes from non-GLP-1 offerings and remains confident in achieving $2.8 billion in 2026 sales.

As the original Magnificent 7 tech stocks face narrowing leadership and stretched valuations, four large-cap companies are emerging as potential new market leaders: Broadcom (AI infrastructure), Eli Lilly (healthcare growth), Oracle (cloud and AI integration), and JPMorgan Chase (financial sector strength). The next phase of market leadership may be more diversified across sectors rather than concentrated in pure-play tech stocks.

Eli Lilly strengthened its leading position in the GLP-1 weight loss drug market with two major developments: Novo Nordisk's CagriSema failed to outperform Lilly's Zepbound in clinical trials, and Lilly launched a new convenient monthly-dose pen format for Zepbound. With 60% U.S. market share and a projected $100 billion market over four years, Lilly is well-positioned for continued growth, though competition from Pfizer and Viking Therapeutics remains a potential threat.

Novo Nordisk announced a 50% price cut on its GLP-1 drugs including Ozempic and Wegovy, reducing list prices to $675/month starting in 2027. The company also partnered with Vivtex Corporation for next-generation oral obesity drugs. However, stock declined following disappointing trial data from REDEFINE 4, hitting a 52-week low.

The article highlights that investors are favoring companies combining high earnings growth (20%+) with strong balance sheets in a market with elevated valuations. NVIDIA is noted as one of the fastest-growing large-cap companies driven by AI accelerator demand, while Eli Lilly has delivered robust earnings growth through innovation in therapeutic areas. The article emphasizes that strong financial foundations combined with significant earnings growth signal durable competitive advantages and offer compelling upside potential with resilience.

While Novo Nordisk is a leader in the GLP-1 drug market with popular products like Wegovy and Ozempic, the article argues the company is unlikely to deliver the 25.89% annual returns needed to turn $100,000 into $1 million over the next decade. The company faces increasing competition from Eli Lilly, its next-gen weight loss drug CagriSema underperformed in trials, and revenue is projected to decline in 2026. However, the stock may still be worth considering as a long-term buy given its diabetes market leadership, deep pipeline, and dividend yield.

Novo Nordisk and United Laboratories announced positive phase 2 trial results for UBT251, a triple agonist obesity drug, showing 19.7% body weight loss in Chinese patients. However, the news comes after Novo Nordisk's stock plunged due to disappointing results from its REDEFINE 4 trial, where CagriSema failed to demonstrate non-inferiority against Eli Lilly's tirzepatide.

Viking Therapeutics' weight-loss drug candidate VK2735 has posted strong mid-stage data and is in phase 3 clinical trials, positioning it as a potential disruptor in the rapidly growing obesity drug market. While the stock could deliver outstanding returns if it successfully navigates clinical and regulatory hurdles, investors should be aware of significant risks including potential clinical setbacks and increased market competition.

Novo Nordisk's stock plummeted 16% after its obesity drug CagriSema underperformed in a head-to-head trial against Eli Lilly's tirzepatide, achieving 23% weight loss compared to 25.5%. The setback sent the stock to its lowest point since 2021, with Deutsche Bank downgrading the company from 'Buy' to 'Hold'. Meanwhile, Eli Lilly gained 4.86% as investors reassessed obesity-drug leaders.